BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2010. The Company also highlighted recent pipeline progress and outlined expected 2011 milestones.
